Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about sourcing dutasteride powder for hair loss treatment, with users suggesting websites like Alibaba and Made-in-China for purchasing. Users discuss the challenges of compounding pills and the legitimacy of online sources.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

Mixing RU58841 powder into minoxidil can result in undissolved particles. Shaking the bottle and breaking up the grains may help dissolve it better.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The conversation discusses the appearance and testing of RU58841 powder for hair loss treatment. Users also mention side effects of RU58841 and suggest alternatives like dutasteride and minoxidil.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Store finasteride powder in a cool, dry place. RU58841 needs to be stored in the freezer.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

The conversation discusses making oral minoxidil from minoxidil powder as a backup plan due to the unavailability of packaged oral minoxidil in Turkey. The user has a capsule machine and some chemistry knowledge but lacks professional equipment.

The user underwent a biopsy two years ago and was diagnosed with keratosis pilaris, leading to hair issues. They tried treatments including Minoxidil, betamethasone, lymecycline, topical Accutane, and dutasteride, as well as diet changes, without improvement in hair thickness or skin dryness.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

The user is experiencing white flakes and a greasy look from using a topical solution containing 0.025% finasteride, 8% minoxidil, 0.01% retinoic acid, and 1% hydrocortisone. Suggestions include reducing application frequency, using a brush to clean the scalp, and considering alcohol-free alternatives.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

The ineffectiveness of Strut Health's dutasteride capsules, which are filled with raw powder instead of liquid and don't contain any buffering agents that would allow for absorption into the bloodstream. It is suggested to use other brands of liquid-filled dutasteride capsules for better results.

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

The user is trying RU58841, oral minoxidil, and dermarolling to combat hair loss caused by increased scalp testosterone after using finasteride and dutasteride. They plan to document their results.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Crushing finasteride pills into stemoxydine may not be effective without removing the coating first. It's unclear if the pills dissolve completely or settle as sediment.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

User seeks KX-826 anti-androgen product and asks for purchase suggestions and experiences. Dave-8D recommends buying powder from the same website and making a topical solution, mentioning possible high dosage from Minoxidil max causing side effects.

The conversation discusses using topical finasteride with propylene glycol, which causes scalp dryness or dandruff. The user also uses Nizoral, Nioxin, and DHT oil, and considers using a scalp conditioner to alleviate dryness.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Zinc pyrithione and piroctone olamine are effective for reducing hair shedding, possibly more so than ketoconazole. There is a concern about zinc pyrithione shampoo interfering with minoxidil, but it's unclear if this is proven.